Jozef Chovanec

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study

Michal Mego, Jozef Chovanec, Iveta Vochyanova-Andrezalova et al. · Complementary Therapies in Medicine · 2015 · 222 citations

Probiotic, Dysbiosis, Medicine +7

Levels of NT‑proBNP in patients with cancer

Jozef Chovanec, Jozef Chovanec, Michal Chovanec et al. · Oncology Letters · 2023 · 17 citations · Full text

Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12®Lactobacillus rhamnosus LGG® in colorectal cancer patients

Michal Mego, Radoslav Danis, Jozef Chovanec et al. · Frontiers in Oncology · 2023 · 12 citations · Full text